Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMRN stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · ILMN FY 2025 (ended Dec 28, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMARIN CORP PLC\UK · implied price per share
Bear
-$0.42
Base
-$0.49
Bull
-$0.56
ILLUMINA, INC. · implied price per share
Bear
$72.96
Base
$85.83
Bull
$98.71
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.22x
0.43x
Net debt / EBITDA
Leverage against operating earnings
6.57x
-0.12x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$1.36B
Total debt
Interest-bearing obligations outstanding
$99.83M
$1.17B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
THERMO FISHER SCIENTIFIC INC.
AMRN vs TMO
AGILENT TECHNOLOGIES, INC.
AMRN vs A
DANAHER CORP /DE/
AMRN vs DHR
BIO-RAD LABORATORIES, INC.
AMRN vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
AMRN vs PACB
Natera, Inc.
AMRN vs NTRA
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMRN can re-rate toward ILMN-like sales multiples or materially improve profitability and growth, then hold or add; otherwise, the data support reducing exposure because AMRN trades at a large premium to the P/S-derived implied value while operating metrics remain weak.
AMRN trades at 29.3x P/S versus ILMN at 5.8x, while the P/S-derived implied price is $2.98 compared with AMRN's current $14.90. That gap is difficult to justify given AMRN's smaller revenue base, negative margins, and negative growth.
Supporting Metrics
